Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth

Proteomic-based drug testing is an emerging approach to establish the clinical value and anti-neoplastic potential of multi-kinase inhibitors. The multikinase inhibitor midostaurin (PKC412) is a promising new agent used to treat patients with advanced systemic mastocytosis (SM). We examined the targ...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Leukemia
Autores principales: Peter, Barbara, Winter, Georg E., Blatt, Katharina, Bennett, Keiryn L., Stefanzl, Gabriele, Rix, Uwe, Eisenwort, Gregor, Hadzijusufovic, Emir, Gridling, Manuela, Dutreix, Catherine, Hoermann, Gregor, Schwaab, Juliana, Radia, Deepti, Roesel, Johannes, Manley, Paul W., Reiter, Andreas, Superti-Furga, Giulio, Valent, Peter
Formato: Artigo
Lenguaje:Inglês
Publicado: 2015
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4896384/
https://ncbi.nlm.nih.gov/pubmed/26349526
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2015.242
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares